NVO
Bearish signalScored 2026-10-06 Drivers: Congress, fundamentals. Insiders: neutral. Moteurs : Congrès, fondamentaux. Initiés : neutre.
Research, not advice.
À propos
Novo Nordisk A/S
- Nom
- Novo Nordisk A/S
- Secteur
- Healthcare
- Industrie
- Drug Manufacturers - General
- Bourse
- NYSE
- Capitalisation
- $172.3B
- Employés
- 68,794
- PDG
- Maziar Mike Doustdar
- Site web
- https://www.novonordisk.com
- Marché
- ABBVAMGNAZNGSKJNJLLY
Novo Nordisk A/S is a global pharmaceutical firm dedicated to the investigation, creation, manufacturing, and distribution of medicinal products across a vast international footprint. Its market presence extends throughout Europe, the Middle East, Africa, various parts of Asia (including Mainland China, Hong Kong, and Taiwan), and North America. The company's operations are structured into two principal business units: Diabetes and Obesity Care, and Rare Disease. The Diabetes and Obesity Care division delivers therapies for diabetes, obesity, cardiovascular ailments, and other emerging therapeutic areas. Meanwhile, the Rare Disease division concentrates on providing treatments for rare blood disorders, uncommon endocrine conditions, and hormone replacement solutions. In addition to its core pharmaceutical offerings, Novo Nordisk produces specialized medical equipment such as insulin pens, growth hormone pens, and injection needles. It also pioneers smart digital solutions for diabetes management, including advanced insulin pens and the Dose Check application, designed to guide insulin dosage. The company engages in strategic alliances, notably a partnership with UNICEF to combat childhood obesity and a collaboration with Valo Health, Inc. to discover and advance novel drug pipelines in the cardiometabolic space. Founded in 1923, Novo Nordisk A/S is headquartered in Bagsvaerd, Denmark.
Price (1 year)
Live chart from TradingView — independent market data, as price context around the filings, not the Quorum score. EMA 50/200 and Bollinger load by default. When the exchange is known it is sent as EXCHANGE:SYMBOL; otherwise TradingView resolves the ticker best-effort.
Decouvert par les declarations du Congres
- Insiders
- —
- Total bought
-
—
Avg buy (VWAP, 90d window) —
- Total sold
-
—
Avg sell (VWAP, 90d window) —
Total sold sums Form 4 code S in this window. Codes F, M, A and G are left out.
- Last activity
- —
- Last synced
-
2026-10-06 10:56:08
Sign in to request a sync of this company's price history and timing levels.
Insider holdings as a share of total assets aren't available for this company.
Avg buy and avg sell are volume-weighted prices (sum of shares × price, divided by shares) for Form 4 rows in this 90-day window that report both figures. A comparison with last close is market context for that average, not advice.
Recent Form 4
Filings in the 90-day window for this company. Value is shares × price from the filing. Research, not advice.
No Form 4 filings for this company in this window.
Congressional trades
STOCK Act disclosures (90-day window)
Amounts are STOCK Act brackets as disclosed. Quorum does not turn a bracket into an exact price or a midpoint.
| Date | Member | Side | Amount range | Filing |
|---|---|---|---|---|
| 2026-08-26 | Scott Franklin | Buy | $1,001 - $15,000 | Filing |
Recent trades
| Date | Representative | Type | Amount |
|---|---|---|---|
| 2026-09-10 | Kevin Hern | Sale | $1,001 - $15,000 |
| 2026-08-31 | Kevin Hern | Sale | $1,001 - $15,000 |
| 2026-08-26 | Scott Mr Franklin | Purchase | $1,001 - $15,000 |
| 2026-08-26 | Scott Franklin | Purchase | $1,001 - $15,000 |
| 2025-10-31 | Lisa C. McClain | Sale (Full) | $1,001 - $15,000 |
| 2025-10-30 | Lisa C. McClain | Purchase | $1,001 - $15,000 |
| 2025-10-30 | Lisa C. McClain | Sale (Full) | $1,001 - $15,000 |
| 2025-10-15 | Marjorie Taylor Greene | Purchase | $1,001 - $15,000 |
| 2025-09-11 | Lisa C. McClain | Purchase | $1,001 - $15,000 |
| 2025-08-28 | Marjorie Taylor Greene | Purchase | $1,001 - $15,000 |
| 2025-08-19 | Marjorie Taylor Greene | Purchase | $15,001 - $50,000 |
| 2025-08-04 | Lisa C. McClain | Sale (Partial) | $1,001 - $15,000 |
| 2025-08-04 | Scott Franklin | Purchase | $1,001 - $15,000 |
| 2025-08-04 | Scott Franklin | Purchase | $15,001 - $50,000 |
| 2025-08-04 | Scott Franklin | Purchase | $1,001 - $15,000 |
| 2025-07-10 | Lisa C. McClain | Sale (Partial) | $1,001 - $15,000 |
| 2025-06-09 | Lisa C. McClain | Purchase | $1,001 - $15,000 |
| 2025-05-08 | Laurel Lee | Sale (Partial) | $1,001 - $15,000 |
| 2025-03-27 | Scott Franklin | Purchase | $1,001 - $15,000 |
| 2025-03-27 | Scott Franklin | Purchase | $15,001 - $50,000 |
| 2025-03-20 | Byron Donalds | Sale (Full) | $1,001 - $15,000 |
| 2025-03-20 | Byron Donalds | Sale (Full) | $1,001 - $15,000 |
| 2024-11-19 | Michael T. McCaul | Sale | $50,001 - $100,000 |
| 2024-10-31 | Michael T. McCaul | Purchase | $15,001 - $50,000 |
| 2024-10-29 | Val Hoyle | Purchase | $1,001 - $15,000 |
| 2024-09-04 | John James | Sale (Full) | $1,001 - $15,000 |
| 2024-08-26 | Michael T. McCaul | Sale | $1,001 - $15,000 |
| 2024-08-09 | Michael T. McCaul | Purchase | $15,001 - $50,000 |
| 2024-05-29 | Michael T. McCaul | Purchase | $15,001 - $50,000 |
| 2024-05-29 | Michael T. McCaul | Purchase | $15,001 - $50,000 |
| 2024-05-28 | Michael T. McCaul | Purchase | $15,001 - $50,000 |
| 2024-05-28 | Michael T. McCaul | Purchase | $15,001 - $50,000 |
| 2024-05-06 | Michael T. McCaul | Purchase | $15,001 - $50,000 |
| 2024-05-06 | Michael T. McCaul | Purchase | $15,001 - $50,000 |
| 2024-02-09 | Ro Khanna | Sale | $50,001 - $100,000 |
| 2023-11-10 | John James | Purchase | $1,001 - $15,000 |
| 2023-09-08 | Ro Khanna | Purchase | $1,001 - $15,000 |
| 2023-07-12 | Daniel Goldman | Sale (Full) | $100,001 - $250,000 |
| 2023-07-10 | Daniel Goldman | Sale (Full) | $250,001 - $500,000 |
| 2023-03-10 | Ro Khanna | Sale | $1,001 - $15,000 |
| 2023-02-10 | Ro Khanna | Purchase | $15,001 - $50,000 |
| 2022-12-05 | Ro Khanna | Sale | $1,001 - $15,000 |
| 2022-10-20 | Ro Khanna | Sale | $1,001 - $15,000 |
| 2022-05-26 | Ro Khanna | Purchase | $1,001 - $15,000 |
| 2022-04-20 | Ro Khanna | Purchase | $1,001 - $15,000 |
| 2021-09-16 | Katherine M. Clark | Sale (Full) | $1,001 - $15,000 |
| 2020-11-05 | Katherine M. Clark | Purchase | $1,001 - $15,000 |
| 2020-02-20 | Mikie Sherrill | Sale (Full) | $1,001 - $15,000 |
| 2019-05-28 | Mikie Sherrill | Sale (Full) | $1,001 - $15,000 |
Signal
Bearish signalScored 2026-10-06 Drivers: Congress, fundamentals. Insiders: neutral. Moteurs : Congrès, fondamentaux. Initiés : neutre.
NVO presents a mixed fundamental picture with solid profitability but deteriorating liquidity metrics (current ratio 0.80, quick ratio 0.57) and a dividend/capex coverage ratio below 1.0, signaling meaningful cash flow…
The first sentence of the analysis written for NVO on 2026-10-06 - a real excerpt, not a sample. The rest of it, the 0-100 score and the rating it produced are part of Plus. See plans.
Factor checklist — research, not advice
A check leans with a bullish reading. A cross leans against it. A dash is unavailable or mixed.
- Insider Unavailable or mixed. No open-market purchase or sale value stored
- Congress Pulls against a bullish reading. STOCK Act sale disclosures outnumber purchases
- Narrative Pulls against a bullish reading. Stored narrative reading is in the bearish band
- Timing Unavailable or mixed. No stored price series
- Financial indicators Unavailable or mixed. Current ratio 0.80 · operating margin 41% — readings disagree
Market snapshot
Financial ratios
| Metric | Trend | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|---|
| Gross Profit Margin | 81.0% | 84.7% | 84.6% | 83.9% | 83.2% | |
| Ebit Margin | 43.6% | 44.4% | 45.3% | 39.2% | 42.2% | |
| Ebitda Margin | 50.7% | 50.9% | 49.4% | 43.4% | 46.4% | |
| Operating Profit Margin | 41.3% | 44.2% | 44.2% | 42.3% | 41.7% | |
| Pretax Profit Margin | 42.2% | 43.8% | 45.1% | 39.0% | 42.0% | |
| Continuous Operations Profit Margin | 33.1% | 34.8% | 36.0% | 31.4% | 33.9% | |
| Net Profit Margin | 33.1% | 34.8% | 36.0% | 31.4% | 33.9% | |
| Bottom Line Profit Margin | 33.1% | 34.8% | 36.0% | 31.4% | 33.9% | |
| Current Ratio | 0.800 | 0.740 | 0.823 | 0.895 | 0.860 | |
| Quick Ratio | 0.570 | 0.552 | 0.636 | 0.693 | 0.663 | |
| Solvency Ratio | 0.357 | 0.373 | 0.448 | 0.399 | 0.435 | |
| Cash Ratio | 0.123 | 0.072 | 0.085 | 0.105 | 0.108 | |
| Price To Earnings Ratio | 14.031 | 27.331 | 36.928 | 38.350 | 35.218 | |
| Price To Earnings Growth Ratio | 8.156 | 1.276 | 0.705 | 2.143 | 2.320 | |
| Forward Price To Earnings Growth Ratio | 8.156 | 1.276 | 0.705 | 2.143 | 2.320 | |
| Price To Earnings Diluted Ratio | 14.049 | 27.379 | 37.028 | 38.460 | 35.302 | |
| Price To Earnings Diluted Growth Ratio | 7.948 | 1.271 | 0.707 | 2.156 | 2.329 | |
| Price To Book Ratio | 7.416 | 19.232 | 29.004 | 25.505 | 23.768 | |
| Price To Sales Ratio | 4.656 | 9.503 | 13.307 | 12.033 | 11.943 | |
| Price To Free Cash Flow Ratio | 49.643 | 39.616 | 44.145 | 33.201 | 35.315 | |
| Price To Operating Cash Flow Ratio | 12.083 | 22.813 | 28.379 | 26.992 | 30.573 | |
| Debt To Assets Ratio | 0.241 | 0.221 | 0.086 | 0.107 | 0.137 | |
| Debt To Equity Ratio | 0.675 | 0.716 | 0.253 | 0.309 | 0.377 | |
| Debt To Capital Ratio | 0.403 | 0.417 | 0.202 | 0.236 | 0.274 | |
| Long Term Debt To Capital Ratio | 0.363 | 0.370 | 0.130 | 0.199 | 0.120 | |
| Financial Leverage Ratio | 2.798 | 3.246 | 2.951 | 2.890 | 2.749 | |
| Working Capital Turnover Ratio | -6.191 | -6.704 | -10.865 | -13.271 | -15.317 | |
| Operating Cash Flow Ratio | 0.552 | 0.556 | 0.642 | 0.652 | 0.553 | |
| Operating Cash Flow Sales Ratio | 0.385 | 0.417 | 0.469 | 0.446 | 0.391 | |
| Free Cash Flow Operating Cash Flow Ratio | 0.243 | 0.576 | 0.643 | 0.813 | 0.866 | |
| Debt Service Coverage Ratio | 7.928 | 9.075 | 16.017 | 73.735 | 4.112 | |
| Interest Coverage Ratio | 30.344 | 78.255 | 189.251 | 197.907 | 202.920 | |
| Short Term Operating Cash Flow Coverage Ratio | 9.911 | 10.273 | 20.533 | 164.348 | 4.276 | |
| Operating Cash Flow Coverage Ratio | 0.909 | 1.177 | 4.033 | 3.060 | 2.064 | |
| Capital Expenditure Coverage Ratio | 1.322 | 2.358 | 2.800 | 5.347 | 7.448 | |
| Dividend Paid And Capex Coverage Ratio | 0.839 | 1.267 | 1.541 | 1.969 | 1.903 | |
| Dividend Payout Ratio | 0.505 | 0.437 | 0.380 | 0.456 | 0.451 | |
| Enterprise Value Multiple | 9.849 | 19.243 | 27.073 | 27.895 | 25.957 |
Sparkline shows each ratio oldest → newest (left → right).
How the latest year compares
For each ratio: its most recent value, the change versus one year earlier, and versus its 5-year average. ▲ higher ▼ lower
| Metric | Current | vs 1Y ago | vs 5Y avg |
|---|---|---|---|
| Gross Profit Margin | 81.0% | ▼-3.7% | ▼-2.5% |
| Ebit Margin | 43.6% | ▼-0.8% | ▲0.7% |
| Ebitda Margin | 50.7% | ▼-0.2% | ▲2.5% |
| Operating Profit Margin | 41.3% | ▼-2.9% | ▼-1.4% |
| Pretax Profit Margin | 42.2% | ▼-1.6% | ▼-0.2% |
| Continuous Operations Profit Margin | 33.1% | ▼-1.6% | ▼-0.7% |
| Net Profit Margin | 33.1% | ▼-1.6% | ▼-0.7% |
| Bottom Line Profit Margin | 33.1% | ▼-1.6% | ▼-0.7% |
| Current Ratio | 0.800 | ▲0.060 | ▼-0.024 |
| Quick Ratio | 0.570 | ▲0.018 | ▼-0.053 |
| Solvency Ratio | 0.357 | ▼-0.016 | ▼-0.045 |
| Cash Ratio | 0.123 | ▲0.051 | ▲0.024 |
| Price To Earnings Ratio | 14.031 | ▼-13.300 | ▼-16.341 |
| Price To Earnings Growth Ratio | 8.156 | ▲6.880 | ▲5.236 |
| Forward Price To Earnings Growth Ratio | 8.156 | ▲6.880 | ▲5.236 |
| Price To Earnings Diluted Ratio | 14.049 | ▼-13.330 | ▼-16.395 |
| Price To Earnings Diluted Growth Ratio | 7.948 | ▲6.677 | ▲5.066 |
| Price To Book Ratio | 7.416 | ▼-11.816 | ▼-13.569 |
| Price To Sales Ratio | 4.656 | ▼-4.846 | ▼-5.632 |
| Price To Free Cash Flow Ratio | 49.643 | ▲10.027 | ▲9.259 |
| Price To Operating Cash Flow Ratio | 12.083 | ▼-10.730 | ▼-12.085 |
| Debt To Assets Ratio | 0.241 | ▲0.021 | ▲0.083 |
| Debt To Equity Ratio | 0.675 | ▼-0.042 | ▲0.209 |
| Debt To Capital Ratio | 0.403 | ▼-0.014 | ▲0.097 |
| Long Term Debt To Capital Ratio | 0.363 | ▼-0.007 | ▲0.126 |
| Financial Leverage Ratio | 2.798 | ▼-0.449 | ▼-0.129 |
| Working Capital Turnover Ratio | -6.191 | ▲0.512 | ▲4.278 |
| Operating Cash Flow Ratio | 0.552 | ▼-0.004 | ▼-0.039 |
| Operating Cash Flow Sales Ratio | 0.385 | ▼-0.031 | ▼-0.036 |
| Free Cash Flow Operating Cash Flow Ratio | 0.243 | ▼-0.333 | ▼-0.385 |
| Debt Service Coverage Ratio | 7.928 | ▼-1.147 | ▼-14.245 |
| Interest Coverage Ratio | 30.344 | ▼-47.911 | ▼-109.391 |
| Short Term Operating Cash Flow Coverage Ratio | 9.911 | ▼-0.362 | ▼-31.957 |
| Operating Cash Flow Coverage Ratio | 0.909 | ▼-0.267 | ▼-1.339 |
| Capital Expenditure Coverage Ratio | 1.322 | ▼-1.036 | ▼-2.533 |
| Dividend Paid And Capex Coverage Ratio | 0.840 | ▼-0.428 | ▼-0.665 |
| Dividend Payout Ratio | 0.505 | ▲0.068 | ▲0.060 |
| Enterprise Value Multiple | 9.849 | ▼-9.394 | ▼-12.155 |
Key metrics
| Metric | Trend | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|---|
| Market cap | $1439.10B | $2759.59B | $3090.69B | $2129.29B | $1681.51B | |
| Enterprise value | $1543.59B | $2846.72B | $3103.30B | $2142.42B | $1697.43B | |
| EV / Sales | 4.99x | 9.80x | 13.36x | 12.11x | 12.06x | |
| EV / Op. cash flow | 12.96x | 23.53x | 28.50x | 27.16x | 30.86x | |
| EV / Free cash flow | 53.25x | 40.87x | 44.33x | 33.41x | 35.65x | |
| EV / EBITDA | 9.85x | 19.24x | 27.07x | 27.89x | 25.96x | |
| Net debt / EBITDA | 0.67x | 0.59x | 0.11x | 0.17x | 0.24x | |
| Current ratio | 0.80x | 0.74x | 0.82x | 0.90x | 0.86x | |
| Income quality | 1.16x | 1.20x | 1.30x | 1.42x | 1.15x | |
| Graham number | $150 | $128 | $100 | $71 | $60 | |
| Graham net-net | -$54 | -$47 | -$24 | -$17 | -$13 | |
| Tax burden | 78.5% | 79.4% | 79.9% | 80.4% | 80.8% | |
| Interest burden | 96.9% | 98.7% | 99.5% | 99.5% | 99.5% | |
| Working capital | -$43.21B | -$56.63B | -$30.01B | -$12.75B | -$13.92B | |
| Invested capital | $295.22B | $216.95B | $121.36B | $105.34B | $84.61B | |
| Return on assets | 18.9% | 21.7% | 26.6% | 23.0% | 24.6% | |
| Operating ROA | 25.3% | 32.9% | 36.9% | 34.3% | 34.6% | |
| Return on tangible assets | 24.8% | 28.5% | 32.9% | 29.2% | 31.6% | |
| Return on equity | 52.8% | 70.4% | 78.5% | 66.5% | 67.5% | |
| Return on invested capital | 29.5% | 39.0% | 54.2% | 49.4% | 43.6% | |
| Return on capital employed | 39.0% | 51.7% | 70.8% | 62.2% | 61.7% | |
| Earnings yield | 7.1% | 3.7% | 2.7% | 2.6% | 2.8% | |
| Free cash flow yield | 2.0% | 2.5% | 2.3% | 3.0% | 2.8% | |
| Capex / Op. cash flow | 75.7% | 42.4% | 35.7% | 18.7% | 13.4% | |
| Capex / Depreciation | 409.9% | 268.5% | 413.2% | 200.4% | 122.6% | |
| Capex / Sales | 29.2% | 17.7% | 16.7% | 8.3% | 5.2% | |
| SG&A / Sales | 22.7% | 23.2% | 26.5% | 28.6% | 29.2% | |
| R&D / Sales | 16.8% | 16.6% | 14.0% | 13.6% | 12.6% | |
| Stock comp / Sales | 0.0% | 0.8% | 0.9% | 0.9% | 0.7% | |
| Intangibles / Total assets | 24.0% | 23.8% | 19.2% | 21.3% | 22.2% | |
| Days sales outstanding | 89d | 110d | 118d | 119d | 121d | |
| Days payables outstanding | 123d | 236d | 261d | 200d | 137d | |
| Operating cycle | 397d | 445d | 443d | 432d | 424d | |
| Cash conversion cycle | 275d | 208d | 182d | 232d | 287d |
Change by theme
Grouped by what each metric measures. Each figure is the change over the period shown — ▲ up ▼ down versus then.
Change over 1 year
Change over 5 years
Employee count
Peer market caps
Recent news
- 2026-10-06 Novo Nordisk A/S $NVO Stock Sold by Eastern Bank Eastern Bank decreased its stake in Novo Nordisk A/S (NYSE: NVO) by 32.8% during the undefined quarter, according to the company in its most recent disclosure with the SEC. The firm owned 82,419 shares of the company''s stock after selling 40,164 shares during the period. Eastern Bank''s holdings in Novo Nordisk A/S were
- 2026-10-05 Novo''s Denecimig BLA Review Delayed by FDA Facility Remediation Work NVO''s denecimig FDA review is delayed by manufacturing facility remediation, while no clinical efficacy or safety deficiencies were identified.
- 2026-10-04 Better High-Yield Dividend Stock: Pfizer or Novo Nordisk? Novo Nordisk is a leading GLP-1 company, but its portfolio beyond that is limited. Pfizer hasn''t entered the GLP-1 race yet, but the company has a diversified business and a long history of success.
- 2026-10-02 US FDA extends review of Novo Nordisk''s hemophilia drug over facility issues The US FDA has extended its review of Novo Nordisk''s experimental hemophilia A drug due to ongoing remediation work at a manufacturing facility, the Danish drugmaker said on Friday.
- 2026-10-02 Novo provides update on the denecimig Biologics License Application (BLA) in the US Bagsværd, Denmark, 02 October 2026 – Novo Nordisk today announced that the US Food and Drug Administration (FDA) has informed Novo that the BLA review of denecimig for the treatment of haemophilia A, with or without inhibitors in adults and children, is still ongoing. The FDA has not communicated a new timeline for expected regulatory action on the BLA.
- 2026-10-02 Novo Nordisk Strikes Nearly $4 Billion in 2 Deals. Here''s What That Means for Investors Novo has improved its pipeline through licensing deals. The recent agreements it has signed could yield powerful, differentiated weight-loss options.
- 2026-10-02 Novo Nordisk vs. Pfizer: Which Healthcare Stock Is a Better Buy in 2026? Novo Nordisk maintains high profitability through its specialization in chronic disease management and metabolic health. Pfizer is aggressively diversifying its portfolio through strategic acquisitions in oncology and obesity to counter upcoming patent expirations.
- 2026-10-02 Why Lilly and Novo are betting on amylin to power a new wave of obesity drugs after GLP-1s Eli Lilly and Novo are developing new amylin drugs that serve as another biological lever to pull in treating obesity and diabetes, either as independent treatments or layered on top of existing drugs. A new slate of injections, pills, and combination regimens target the amylin pathway, which involves a hormone released in the pancreas alongside insulin that helps regulate hunger and fullness.
- 2026-10-02 LLY Highlights New Efficacy Data From Foundayo and EloraTZP Studies Eli Lilly''s new data show Foundayo''s cardiovascular safety and metabolic benefits, while EloraTZP delivers greater weight loss and A1C reduction in a mid-stage study.
- 2026-10-02 Eli Lilly obesity drug data adds pressure on Novo Nordisk Novo Nordisk (NYSE:NVO) faces further pressure in the obesity-drug market after Eli Lilly and Co (NYSE:LLY) reported promising mid-stage data for an experimental treatment that delivered greater weight loss than tirzepatide alone. EloraTZP, a combination of eloralintide and tirzepatide targeting amylin, glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1 pathways, produced weight loss of up to 23.3% after 48 weeks in overweight or obese patients with type 2 diabetes.